Al's Comment:

These patients were MGMT unmethylated, and did not have a complete resection - which puts them in an unfavorable prognostic group. These numbers look very good for that group.

---

Posted on: 02/02/2024

 TME Pharma Announces Final Median Overall Survival Data Reaching 19.9 Months for NOX-A12 Combination Regimen in GLORIA Brain Cancer Trial and Survival Rate 10-Fold Greater Than Standard of Care 

 

---

Click HERE to return to brain tumor news headlines.